WW Beats Estimates as Subscribers Decline

WW International reported third-quarter 2026 earnings of $1.51 per share, above the 66-cent Wall Street estimate, even as revenue fell 11.2%.

Updated on Nov. 6, 2026 in Weight Loss

WW Beats Estimates as Subscribers Decline

Live Poll

Would you pay for a weight-loss program if you already take GLP-1 medication?

WW International reported third-quarter 2026 earnings of $1.51 per share, well ahead of the 66-cent Wall Street estimate. Revenue fell 11.2% year over year to $152.9 million, and the company's shares fell 2.65% to $12.50 in premarket trading.

Why it matters

The results show a shift in the company's business mix, with clinical subscriptions growing while behavioral subscriptions decline. The company is positioning itself to serve customers who obtain weight-loss medications from other sources, focusing on nutrition, behavioral coaching and community support.

Total subscribers stood at approximately 2.3 million, with behavioral subscribers down 26% to 2.1 million, while Core+ subscribers reached 546,000. The company has not yet shown whether clinical subscription growth can offset the behavioral decline.

The players

WW International

WW International is a weight-management company that offers behavioral and clinical subscription programs to help customers lose weight and maintain healthy habits.

The details

Clinical subscription revenue rose 48% to $38 million, while behavioral subscription revenue fell 22% to $113.9 million. Management linked the quarterly decline in clinical subscribers to subscription renewals and changes in marketing spending, and marketing expenses fell to $33.1 million from $48.4 million a year earlier.

January 2026: Core+ enrollment in the GLP-1 Success Program began doubling.
June 2026: Clinical subscribers stood at 197,000 before the quarterly decline.
Q3 2026: Third-quarter results were reported Thursday, beating estimates.
Fourth quarter 2026: Marketing spending is set to increase ahead of the 2027 peak season.
2027: The company aims to restore sustainable, profitable growth.

Health Landscape

The company's shift toward clinical support reflects a broader change in how weight-loss care is delivered, as GLP-1 medications become more widely used. WW's growth in its GLP-1 Success Program signals that traditional diet-based subscriptions are being reshaped around prescription treatments.

Customers using weight-loss medications may find more support options through nutrition, behavioral coaching and community programs, regardless of where they obtain their prescriptions. The company's narrowed 2026 revenue forecast of $625 million-$630 million signals continued pressure on the business.

The takeaway

WW's results suggest that weight-loss support is moving beyond diet plans toward programs that work alongside prescription medications. Readers considering a program should compare what each service offers for medication users and non-users.

What happens next

The company expects marketing spending to increase in the fourth quarter as it prepares for its 2027 peak season, and it aims to restore sustainable, profitable growth in 2027.